Bacteremic Pneumonia in Neutropenic Patients With Cancer: Causes, Empirical Antibiotic Therapy, and Outcome
The DOI matches its Crossref record.
Abstract
BACKGROUND: Bacteremic pneumonia is a major cause of death among neutropenic patients with cancer. METHODS: We analyzed the causes, empirical antibiotic therapy, and outcome of 40 consecutive cases of bacteremic pneumonia identified among 408 episodes of bacteremia in adult neutropenic patients with cancer, prospectively documented from 1986 to 1995. RESULTS: The most frequent causative organisms were Pseudomonas aeruginosa (17 cases), Streptococcus pneumoniae (12 cases), Escherichia coli (5 cases), and Streptococcus mitis (3 cases). Overall, P. aeruginosa and S. pneumoniae caused 72.5% of all episodes of bacteremic pneumonia, compared with 11.4% of bacteremic episodes from other sources (P< .001). Thirty patients received ceftazidime and 10 patients received imipenem as the beta-lactam component of the initial empirical treatment. All strains of P. aeruginosa were susceptible to both agents. Forty-seven percent of streptococcal strains were penicillin resistant and showed a decreased susceptibility to ceftazidime (minimum inhibitory concentration ranged from 1 to 64 microg/mL). Five patients (12.5%) were considered to have received inappropriate empirical antibiotic therapy. Attributable mortality in patients with bacteremic pneumonia was higher than in patients with bacteremia from other sources; 22 (55%) of the 40 patients with bacteremic pneumonia died, whereas 39 (10.6%) of the 368 patients with bacteremia from other sources died (P<.001). CONCLUSIONS: Our data suggest that bacteremic pneumonia in neutropenic cancer patients is associated with a poor outcome and that empirical antibiotic therapy for neutropenic patients with pneumonia should include agents active against both P. aeruginosa and cephalosporin-resistant streptococci.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Wisplinghoff, H., Bischoff, T., Tallent, S. M., Seifert, H., Wenzel, R. P., & Edmond, M. B. (2004) · Clinical Infectious Diseases · doi:10.1086/421946 · Cited by 4,496
Freifeld, A. G., Bow, E. J., Sepkowitz, K. A., Boeckh, M. J., Ito, J. I., Mullen, C. A., Raad, I. I., Rolston, K. V., Young, J.-A. H., & Wingard, J. R. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir073 · Cited by 3,463
Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients
Kuderer, N. M., Dale, D. C., Crawford, J., Cosler, L. E., & Lyman, G. H. (2006) · Cancer · doi:10.1002/cncr.21847 · Cited by 1,176
Kuderer, N. M., Dale, D. C., Crawford, J., & Lyman, G. H. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.8823 · Cited by 720
Freifeld, A. G., Bow, E. J., Sepkowitz, K. A., Boeckh, M. J., Ito, J. I., Mullen, C. A., Raad, I. I., Rolston, K. V., Young, J.-A. H., & Wingard, J. R. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/ciq147 · Cited by 704
Wisplinghoff, H., Seifert, H., Wenzel, R. P., & Edmond, M. B. (2003) · Clinical Infectious Diseases · doi:10.1086/374339 · Cited by 687
“Increasing resistance to penicillin and other b-lactam antibiotics has been documented in viridans group streptococci isolated from neutropenic patients with cancer [26, 33].”
BackgroundResultCystic Fibrosis and Pseudomonas aeruginosa: the Host-Microbe Interface
Malhotra, S., Hayes, D., & Wozniak, D. J. (2019) · Clinical Microbiology Reviews · doi:10.1128/cmr.00138-18 · Cited by 515
ExsE, a secreted regulator of type III secretion genes in Pseudomonas aeruginosa
Rietsch, A., Vallet-Gely, I., Dove, S. L., & Mekalanos, J. J. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503005102 · Cited by 374
Hung, Y.-P., Lee, C.-C., & Ko, W.-C. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.869822 · Cited by 29
Metadata
- Authors
- Carratalà, J., Rosón, B., Fernández-Sevilla, A., Alcaide, F., & Gudiol, F.
- Venue
- Archives of Internal Medicine
- Publisher
- American Medical Association (AMA)
- Published
- 1998-04-27
- Volume
- 158
- Issue
- 8
- Pages
- 868
- ISSN
- 0003-9926 (ISSN-L)
- OpenAlex
- W2138267332
- Cited by
- 133
- References
- 0
- FWCI
- 2.25
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.